Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: Results from a US database of over 45 000 HCV-infected, evaluated patients

A. H. Talal, J. Lafleur, R. Hoop, P. Pandya, P. Martin, I. Jacobson, J. Han, E. J. Korner

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint Dive into the research topics of 'Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: Results from a US database of over 45 000 HCV-infected, evaluated patients'. Together they form a unique fingerprint.

Medicine & Life Sciences